VAV1 Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P15498 |
---|---|
Clone Names | 100427270 |
Gene ID | 7409 |
---|---|
Other Names | Proto-oncogene vav, VAV1, VAV |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13853c was selected from the Center region of VAV1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | VAV1 |
---|---|
Synonyms | VAV |
Function | Couples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation and/or proliferation. |
Tissue Location | Widely expressed in hematopoietic cells but not in other cell types |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this proto-oncogene is a member ofthe Dbl family of guanine nucleotide exchange factors (GEF) for theRho family of GTP binding proteins. The protein is important inhematopoiesis, playing a role in T-cell and B-cell development andactivation. This particular GEF has been identified as the specificbinding partner of Nef proteins from HIV-1. Coexpression andbinding of these partners initiates profound morphological changes,cytoskeletal rearrangements and the JNK/SAPK signaling cascade,leading to increased levels of viral transcription and replication.
References
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Hollmann, A., et al. Hematol Oncol 28(3):142-150(2010)Barda-Saad, M., et al. EMBO J. 29(14):2315-2328(2010)Davila, S., et al. Genes Immun. 11(3):232-238(2010)Kim, H.S., et al. Immunity 32(2):175-186(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.